Orforglipron: The Definitive Guide

What is orforglipron?

Orforglipron is a once-a-day prescription pill for weight loss, sold by Eli Lilly as Foundayo. It switches on the receptor for GLP-1, a hormone your gut releases after you eat, which lowers appetite and helps control blood sugar. Unlike earlier GLP-1 medicines such as semaglutide, it is not a peptide. [1], [2], [3]

GLP-1 stands for glucagon-like peptide-1. Every earlier GLP-1 medicine, including semaglutide (Ozempic, Wegovy) and liraglutide, is a peptide: a chain of amino acids, much like the natural hormone. Peptides are easily broken down in the gut, so most are injected, and semaglutide tablets need an absorption helper and strict fasting rules. Orforglipron is a small molecule, built from scratch in a laboratory to fit the same receptor. About three-quarters of a swallowed dose reaches the blood, and the label allows it to be taken at any time of day, with or without food. [1], [3], [4]

The molecule was discovered by the Japanese company Chugai under the code OWL833 and licensed to Lilly in 2018, which developed it as LY3502970. The US Food and Drug Administration (FDA) approved it on April 1, 2026, and the UK approved it in August 2026. [5], [6], [2], [7]

[1], [8], [9], [10]

People also come across orforglipron as "research" capsules, powders or pills sold online, sometimes mixed with other compounds. These are not approved products, their contents have not been checked, and their milligram amounts often come from trial capsules rather than Foundayo tablets. [11], [12], [13]

Typical Orforglipron Protocols

The most common schedule in the labels and the reviewed dosing sources is one tablet a day, starting at 0.8 mg and rising at least 30 days apart through 2.5 mg to 5.5 mg, with further 30-day steps to 9, 14.5 and 17.2 mg if more effect is needed and the side effects allow. [1], [8], [14], [15], [16], [17]

Titration Raising the dose in steps

The slow start is there to limit nausea, vomiting and diarrhea, which were most common while the dose was rising. Each step lasts at least 30 days; there is no maximum time on a step. The US label says to move from 2.5 mg to 5.5 mg after at least 30 days, and then to go higher only "based on treatment response and tolerability"; the UK wording says the move to 5.5 mg "can" be made. 5.5, 9, 14.5 and 17.2 mg can each be a long-term maintenance dose. [1], [8]

Breaks and cycles

Not applicable in the labels: orforglipron is a continuous, long-term treatment with no planned breaks. If a tablet is missed, both labels say to take it as soon as possible and never to take two in one day. The US label adds that after 7 or more missed days in a row, the dose steps restart at a lower dose to limit stomach side effects. Weight tends to return after GLP-1 medicines are stopped (see stopping). [1], [8], [18]

Read the units: doses are in milligrams (mg) per tablet, and one tablet is the whole daily dose. There are no syringe units, no mixing and no splitting: the labels say to swallow the tablet whole and never to take more than one a day, including to make up a higher dose. Trial capsule milligrams are not the same as tablet milligrams: a 36 mg trial capsule gives the same blood levels as a 17.2 mg Foundayo tablet (see the conversion table). [1], [8], [19]

Each row is a labeled schedule, not a step to move through. These are the labeled doses; prescribers move up the steps based on weight or blood-sugar response and side effects, and hold at a lower maintenance dose when that works. [1]

What do the trial doses mean in tablets?

Almost every published orforglipron study used an earlier investigational capsule form with its own milligram numbers. The capsules and the Foundayo tablets give matching amounts of drug in the blood, but the numbers on the pack are different. That is why news stories and older pages quote 6, 12 or 36 mg while pharmacies dispense 5.5, 9 or 17.2 mg. [19], [20], [8]

In this guide, trial results keep the trial's own capsule dose and give the matching tablet in brackets, for example "36 mg (17.2 mg tablet)". [19]

Where schedules differ: switching from injections, missed doses, research capsules and stopping ↓

What is orforglipron commonly used for?

Most people look into orforglipron because they want to lose weight without injections, or to keep off weight they lost on an injectable GLP-1 medicine. People with type 2 diabetes also read about it, because several large trials tested it for blood-sugar control. In community education groups, members often describe it as a convenient pill that they expect to work less strongly than the newest injections; no completed trial has compared it directly with those injections for weight loss (see the comparison). [1], [25], [26]

The uses below are approved for specific people in specific countries. Using orforglipron outside its label, or using an unapproved "research" product, is a different situation from the trials described here.

Weight loss

This is Foundayo's only US use. The label covers adults with obesity, or with overweight plus at least one weight-related health problem such as high blood pressure or sleep apnea, alongside a reduced-calorie diet and more physical activity. In ATTAIN-1, adults without diabetes lost an average of 7.4%, 8.3% and 11.1% of their body weight over 72 weeks on the 5.5, 9 and 17.2 mg tablet-equivalent doses, compared with 2.1% on placebo. On the top dose, 54.5% lost at least 10% of their weight and 18.4% lost at least 20%. [1], [27]

Doserly

How much weight did people lose in the main trials?

Randomized human trials; each result against that trial's own placebo group

ATTAIN-1 · Adults without diabetes (3,127 people)

5.5 mg −7.4%; 9 mg −8.3%; 17.2 mg −11.1%; placebo −2.1%.

ATTAIN-2 · Adults with type 2 diabetes (1,613 people)

5.5 mg −5.1%; 9 mg −7.0%; 17.2 mg −9.6%; placebo −2.5%.

Average change in body weight (%).

Average change over 72 weeks; each trial had its own placebo group. Trial capsule doses in brackets.

Weight loss rose with the dose; people with type 2 diabetes lost less.

Keeping weight off after injections

Many people who lose weight on weekly injections want a simpler way to keep it off. The ATTAIN-MAINTAIN trial tested exactly that. Adults who had lost weight on tirzepatide (Zepbound) or semaglutide (Wegovy) in an earlier trial stopped their injections and were assigned by chance to daily orforglipron or placebo for a year. Among those whose weight had leveled off before switching, the orforglipron groups kept an estimated 74.7% (after tirzepatide) and 79.3% (after semaglutide) of the weight they had lost, compared with 49.2% and 37.6% on placebo. These are statistical model estimates for the group, not the result for each person. [25]

The trial had no group that simply stayed on injections, so it cannot show whether switching works as well as continuing, and it lasted only a year. People on placebo who regained enough weight could be moved to orforglipron from week 24. [25]

Doserly

How much earlier weight loss did people keep after stopping injections?

Randomized human trial (ATTAIN-MAINTAIN); model-based estimates at week 52

After tirzepatide (Zepbound)

Orforglipron 74.7%; placebo 49.2%.

After semaglutide (Wegovy)

Orforglipron 79.3%; placebo 37.6%.

Among people whose weight had leveled off on injections before they switched.

No group continued injections. Placebo participants who regained enough weight could receive orforglipron from week 24.

People who switched to orforglipron kept more of their earlier weight loss than those given placebo.

Type 2 diabetes

In the UK, Foundayo is also approved for adults with type 2 diabetes whose blood sugar is not controlled well enough, on its own or with other diabetes medicines. In the US, it is not approved for diabetes as of September 2026, although the label notes that it lowers blood sugar. In ACHIEVE-1, adults with early type 2 diabetes saw HbA1c fall by 1.24 to 1.48 points over 40 weeks, compared with 0.41 on placebo. In ACHIEVE-3, it lowered HbA1c more than semaglutide tablets. [8], [7], [1], [26], [28]

Other conditions being studied

Lilly has registered trials of orforglipron in obstructive sleep apnea, high blood pressure, knee arthritis pain, leg-artery disease, heart disease outcomes and teenagers with obesity. Most have not reported results; see the registered studies. [29], [30], [31], [32], [33], [34]

Where do orforglipron protocols differ?

The label ladder is simple. The confusion comes from two dose scales (capsules and tablets), how to switch from an injection, different missed-dose rules by country, research products, and stopping.

Doserly

How do Foundayo tablet doses step up?

Official Foundayo product labels (US and UK) and the FDA review

0.8 mg tablet

Start, at least 30 days · trial capsule 1 mg

2.5 mg tablet

Step, at least 30 days · trial capsule 3 mg

5.5 mg tablet

Maintenance option, at least 30 days · trial capsule 6 mg

9 mg tablet

Maintenance option, at least 30 days; top dose with some interacting medicines · trial capsule 12 mg

14.5 mg tablet

Maintenance option, at least 30 days · trial capsule 24 mg

17.2 mg tablet

Maximum maintenance option, at least 30 days · trial capsule 36 mg

45 mg capsule (phase 2 only): no tablet equivalent

Tablet mg and trial capsule mg are separate scales: the 36 mg trial capsule gives the same blood levels as the 17.2 mg tablet.

Each step lasts at least 30 days; higher doses only if needed and tolerated.

Is 36 mg the same as 17.2 mg?

Matched in blood levels, not in milligrams. A 36 mg trial capsule and a 17.2 mg Foundayo tablet give matching blood levels, and the UK label states that the two forms "are not substitutable on a mg-per-mg basis". The same applies down the scale: 12 mg matches 9 mg, and 6 mg matches 5.5 mg. There is no 36 mg Foundayo tablet. [19], [8]

The mix-up shows up widely. One dosing page lists "36 mg once daily at maintenance" under FDA-approved Foundayo, and another pairs a "12–36 mg" trial range with a vial calculator. In community education groups, one course table starts at the 0.8 mg tablet but gives 36 mg, a capsule dose, as the top of the range. Taking the trial number at face value with tablets would mean about double the top approved dose, and it cannot be done anyway without taking several tablets a day, which the labels forbid. [22], [23], [8]

Does everyone need to reach 17.2 mg?

No. 5.5, 9 and 14.5 mg are all labeled maintenance doses, and the label allows a person to stay on the dose that works and is tolerated. In ATTAIN-1, 59.6% of people on 5.5 mg lost at least 5% of their weight, compared with 71.5% on 17.2 mg and 26.8% on placebo. [1]

The doses matter more in type 2 diabetes. In the FDA's review of ATTAIN-2, the lowest dose's extra weight loss over placebo (about 2.6%) was judged not clinically significant, and the middle dose's (about 4.5%) borderline, while the top dose gave about 7.1%. That is the agency's view of one trial, not a rule for every person. [19], [1], [35]

How do people switch from an injection?

The labels give no switching instructions: every new Foundayo user starts at 0.8 mg. [1], [8]

The switch trial did it differently. In ATTAIN-MAINTAIN, people started orforglipron within 14 days of their last injection at a 12 mg capsule (the 9 mg tablet's match) and moved up every 4 weeks toward 36 mg (17.2 mg tablet) or the highest dose they tolerated. That is a research protocol for people already used to GLP-1 side effects, not an approved schedule. Some clinic pages now describe it to patients. [25], [36]

In public forums and community education groups, people who switched straight to the lowest tablet strengths often described hunger returning and small gains at first (see what people report). The starting doses are there to limit side effects, not to match an injection. [37], [38], [39], [40]

What if a tablet is missed?

The rules differ slightly by country. Both labels say to take a missed tablet as soon as possible and never to take two tablets in one day. The US label adds that after 7 or more missed days in a row, the dose steps start again from a lower dose; the patient guide says to call the prescriber about how to restart. [1], [8]

Because orforglipron's half-life is 29 to 49 hours, blood levels roughly halve within one to two days of a missed tablet. One person who tried a claimed research pill described hunger returning when a dose was taken about four hours late; they later softened the claim in the comments, and the product was never tested. [1], [41]

Do "research" capsules and pills follow the same steps?

No. Research products are sold in their own strengths, often 6 mg capsules or pills, and websites give their own schedules: [11], [12], [24], [42]

• A split-pill ladder: a quarter of a 6 mg pill (1.5 mg) in week 1 and half a pill in week 2, then whole pills rising by 6 mg every 4 weeks to six pills (36 mg) a day, followed by a break as long as the course. [11]
• A combination pill: 6 mg of orforglipron with 250 mcg of SLU-PP-332, every other day in week 1, then daily, then two pills a day from week 11. This mix has its own guide. [12]
• A compounded capsule: a pharmacy page describing 1–3 mg a day to start, increased every 4–8 weeks, with a 12 mg capsule as a possible maintenance strength. [24]
• A "typical" 2 mg: one page averages early trial doses into a "typical" 1–3 mg a day. [42]

In community education groups, members most often described grey-market 6 mg capsules taken five to seven times a week, sometimes as a "bridge" between courses of injectable drugs. None of these schedules has been tested, and none matches the approved tablets, which must not be split. Even if genuine, a 6 mg capsule would match a 5.5 mg tablet, far above the 0.8 mg starting dose. The contents of these products are unverified; see product quality. [1], [19]

Can you cut, crush or "microdose" the tablets?

The labels say no: swallow each tablet whole and do not break, crush or chew it. Foundayo comes in six strengths so that lower doses do not require cutting. No study has tested split tablets or doses below 0.8 mg. [1], [8], [17]

What happens when you stop orforglipron?

The labels describe long-term treatment, and there is no published study of what happens to weight after people stop orforglipron itself. The main trials followed people for only 2 weeks after the last dose, to check safety. With a half-life of 29 to 49 hours, most of the drug is gone within a week or two of the last tablet; the UK label asks women to stop at least 3 weeks before a planned pregnancy for this reason. [1], [8], [19]

• What the switch trial shows about stopping injections. In ATTAIN-MAINTAIN, the placebo groups had in effect stopped GLP-1 treatment: over a year, those whose weight had leveled off before switching kept an estimated 37.6% to 49.2% of the weight they had lost, versus 74.7% to 79.3% on orforglipron. [25]
• What happens across GLP-1 medicines. A 2026 review of stopping studies, all of injectable medicines, estimated that about 60% of lost weight returns within a year, leveling off near 75%. It cannot say exactly how orforglipron behaves. [18]
• Blood sugar. No study has reported what happens to HbA1c after stopping orforglipron.
• A planned test. In two high-blood-pressure trials, people who have taken orforglipron for 48 weeks will be reassigned by chance to continue or switch to placebo for 12 weeks. The planned stopping outcome is blood pressure, not weight. [43]

Tapering, breaks and "receptor resets." The labels give no taper schedule, and no study has compared tapering with stopping at once. Some research-product pages build in long breaks between courses. In community education groups, several members described taking orforglipron during planned breaks from injectable drugs; educators there pointed out that a break on a drug acting on the same receptor does not "reset" it. No study shows that breaks restore the effect. [1], [11], [25]

Why can orforglipron be a pill with no fasting rules?

Because it is a small molecule, not a peptide. Foundayo is taken orally (swallowed), once a day, at any time, with or without food or water; it is not made as an injection, and the US label says it is "only for oral use". [1], [8]

Peptide GLP-1 drugs struggle in the gut. Only about 1% to 2% of a Wegovy semaglutide tablet reaches the blood, even with its absorption helper, so those tablets must be taken on an empty stomach with a little water and a 30-minute wait. Orforglipron was designed to be absorbed like an ordinary pill: its absolute bioavailability was 77% after a 0.8 mg dose in the label's analysis, and 79% after a 1 mg capsule in a separate tracer study. [4], [1], [44]

Food makes little difference. With a meal, total exposure fell by 19% and peak levels by 26% in a study of an investigational tablet, which the FDA judged not clinically relevant; an earlier capsule study found similar drops of 18% to 24%. Stomach-acid reducers such as esomeprazole had no effect on it. [1], [45]

Lilly describes Foundayo as the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. In community education groups, some lessons still repeat the peptide rule of taking an oral GLP-1 on an empty stomach, or say high doses are needed because stomach acid destroys it; neither applies to orforglipron. [6], [1]

What does a 29- to 49-hour half-life mean?

Half-life is the time it takes for the level in the blood to fall by half. For orforglipron it is about 29 to 49 hours, so a daily tablet keeps levels fairly even, and they level off (steady state) after about a week. Levels peak 4 to 8 hours after each tablet. Half-life is one part of a drug's pharmacokinetics: how the body absorbs, moves, breaks down and removes it. [1]

The shorter half-life compared with weekly injections has two practical sides. A missed tablet matters sooner than a late weekly injection, and the drug also clears sooner after stopping or after an overdose; the label advises observation "considering the half-life". [1]

How does the body clear it?

The liver breaks orforglipron down, mainly through an enzyme called CYP3A4, and the breakdown products leave in the stool: 87% of a test dose came out in feces and less than 1% in urine. That explains two label rules. [1], [44]

• Kidneys: kidney disease, even needing dialysis, did not change blood levels, so no dose change is needed. [1]
• Liver: moderate liver disease raised total exposure 1.7-fold and severe liver disease 4.6-fold. It is not recommended with severe liver impairment. [1], [8]
• Other medicines: anything that blocks or speeds up CYP3A4 changes orforglipron levels (see interactions). [1]

How should orforglipron be stored, and how long does it last?

The label for the pack in your hand is the final word, because storage rules differ by country and pack, and the US wording changed in 2026. [1], [21], [8]

[1], [21], [8]

The removal of the US light warning does not show that light has no effect on every pack; it is the current wording for the US bottle, which already keeps light out. Keeping tablets in their original container until you take them follows both labels. [1], [8]

Research capsules and powders. No approved label covers them, so they have no tested storage period. One dosing page applies a generic storage framework for freeze-dried peptides, which does not fit a tablet or a small molecule. [46]

What do we actually know about orforglipron in people?

Quite a lot for a new medicine. Orforglipron has been tested in large randomized controlled trials, where people are assigned by chance to the medicine or a comparison. As of September 24, 2026, ClinicalTrials.gov lists 52 orforglipron studies, 50 of them sponsored by Lilly, and 27 with posted results. A pooled safety analysis of the phase 3 program covered 11,220 people. The questions the trials answer are specific: how much weight or blood sugar changes, in whom, at which dose, and against what comparison. [47], [48]

How much weight do people lose in trials?

An average hides a wide range. In ATTAIN-1, 71.5% of people on the top dose lost at least 5% of their weight and 35.9% lost at least 15%, while about 3 in 10 lost less than 5%. Average loss was lower at every dose in ATTAIN-2, the trial in people with type 2 diabetes; because the two were separate trials, the reason is not isolated. In a later analysis of adults aged 65 and older in ATTAIN-1, average loss on the top dose was 13.0%. [1], [51]

Why do some sources say placebo lost 0.9%? Trials can be analyzed in two ways. The "treatment regimen" approach counts everyone assigned to a group, including people who stopped taking the tablets; it is the main result in the label and the journal, and gives −11.1% or −11.2% on the top dose versus −2.1% on placebo. The "efficacy estimand" counts only what happened while people kept taking their assigned treatment: in the FDA's review, −12.35% on the top dose versus −0.87% on placebo. Both are correct; the numbers just cannot be mixed. The label also rounds some values slightly differently from the journal (for example −7.4% versus −7.5% on the lowest dose). [1], [27], [19]

What happens to blood sugar in type 2 diabetes?

HbA1c, a blood test that reflects average blood sugar over about three months, fell in every diabetes trial:

Added to insulin in ACHIEVE-5, orforglipron did not increase clinically significant low blood sugar: 12.9% to 19.0% of people on orforglipron had it, versus 20.7% on placebo, though 3 people on orforglipron had a severe episode. [53], [8]

In ACHIEVE-3, the only completed head-to-head trial against another GLP-1 pill, both orforglipron doses lowered HbA1c more than both semaglutide doses. Stomach and bowel side effects were more common with orforglipron (59% and 58%) than with semaglutide tablets (37% and 45%), and more people stopped because of side effects (9% and 10% versus 4% and 5%). This reverses a claim, repeated on some pages, that orforglipron causes about half the stomach side effects of oral semaglutide. The trial was open-label (everyone knew which drug they took) and used diabetes doses of semaglutide, not the 25 mg weight-loss tablet. [28]

Does it help blood pressure, cholesterol and the heart?

The weight trials measured several heart-risk factors. On the top dose in ATTAIN-1, over 72 weeks: [1]

• Waist: −10.0 cm versus −3.1 cm on placebo.
• Systolic blood pressure (the top number): −6.4 versus −1.4 mmHg.
• Triglycerides (a blood fat): −20.0% versus −4.0%; non-HDL cholesterol −7.7% versus −2.0%; HDL ("good") cholesterol +4.5% versus −1.0%.
• Pulse: +4.6 versus +0.6 beats per minute (see heart rate).

Fewer outcomes are known. ACHIEVE-4, which compared orforglipron with insulin glargine in 2,749 adults with type 2 diabetes and heart risk, met its preset non-inferiority goal for heart attacks, strokes and related events: it ruled out a large increase compared with insulin (hazard ratio 0.84, with a range from 0.59 to 1.20, inside the preset limit of 1.8). Because that range runs from about 40% fewer to 20% more events, it does not show a heart benefit and does not rule out a small increase. The result comes from a company announcement, with a full presentation scheduled for October 2026; it is not yet a journal paper. A larger heart-outcomes trial against placebo, in about 7,140 people, is under way. [55], [56], [33]

Is the weight lost fat or muscle?

Mostly fat, but lean tissue fell too. In a body-scan substudy of ATTAIN-1 (171 people scanned with DXA), fat mass fell by 13.8% on orforglipron across doses and 1.7% on placebo over 72 weeks, while lean mass (muscle, organs and water) fell by 4.5% versus rising 0.3%. On the top dose, fat fell 20.0% and lean mass 6.6%. The FDA reviewer noted that fat loss was about three times the lean loss, similar to other weight-loss treatments, and saw no sign of excessive muscle loss; falls were reported in 1% of people on orforglipron and 0.7% on placebo. [19], [1]

Lean mass is not the same as strength, and no orforglipron study has measured strength. In community education groups, educators stress protein and strength training during large weight loss, especially for older adults and athletes.

Which studies are still under way?

How does orforglipron work?

Orforglipron switches on the GLP-1 receptor, the same receptor as the natural hormone and as semaglutide. Its effects in people are measured: it reduces food intake, most likely by lowering appetite; it raises insulin only when blood sugar is high and lowers fasting glucagon (a hormone that raises blood sugar); and it slows how fast the stomach empties. [1], [8]

How does a small molecule switch on a peptide receptor?

In a 2020 laboratory study, researchers took a high-resolution picture of orforglipron (then LY3502970) bound to the human GLP-1 receptor. It sat in a pocket in the upper part of the receptor, held by the receptor's outer arm (the extracellular domain), one of its outer loops and four of its seven helices. That grip creates a slightly different receptor shape from the one the natural hormone creates. [3]

Two consequences follow in laboratory tests. Orforglipron is a partial agonist: it switches the receptor on less fully than GLP-1, yet only a small share of receptors needs to be occupied for a full effect on blood sugar in mice with the human receptor. It is also "biased": it triggers the receptor's main signaling route (through G proteins) while barely recruiting beta-arrestin, a protein that helps pull receptors inside the cell. Whether this bias changes anything for patients is not known. The FDA also describes it as a partial agonist. [3], [60], [2]

Why were most animal studies done in special mice and monkeys?

The grip depends on one amino acid in the receptor's outer arm that primates have and rodents lack. Orforglipron does nothing at normal rat and mouse GLP-1 receptors, so researchers used mice and rats engineered to carry the human-type receptor, and monkeys. In those animals, oral doses lowered blood sugar, raised insulin and reduced food intake, with effects comparable to an injected GLP-1 drug (exenatide). In rats engineered this way, orforglipron by mouth kept weight down after injected semaglutide was stopped. [3], [60], [61], [1]

This also explains the rodent safety data. Orforglipron caused no tumors in a 2-year rat study or a 26-week mouse study, but because it cannot act on rodent receptors, those studies cannot answer the thyroid question raised by other GLP-1 drugs (see thyroid risk). [1]

How does it reduce appetite?

GLP-1 receptors sit in brain areas that regulate appetite. In animal studies, orforglipron reached and activated nerve cells in those areas. In a 2026 study of a brain reward circuit, oral orforglipron reduced high-fat food intake and body weight in mice engineered so their receptor responds to it. How much of the effect in people comes from the brain versus the stomach has not been measured directly. [1], [62]

Does it slow the stomach?

Yes, mostly at first. The label states that the delay in stomach emptying is largest after the first dose and fades with continued use. In one test, the first 0.8 mg dose lowered the peak level of acetaminophen (a marker of how quickly a pill leaves the stomach) by 28%; the effect was smaller after repeated doses of 17.2 mg. This slowing is why the label warns about anesthesia and about birth-control pills. [1]

Other laboratory findings

Small numbers of preclinical (laboratory and animal) studies have looked at other effects: less aortic aneurysm damage in mice with the human-type receptor, and protective, anti-inflammatory effects in laboratory cell experiments. In rats, very little of the drug crossed into the brain (a brain-to-blood ratio of 0.0078), though rats cannot show its effects there. In type 2 diabetes, an analysis of the phase 2 trial found markers of insulin-making cell function and insulin sensitivity improved. None of these findings is a proven benefit in people. [63], [64], [65]

What are the risks and unanswered questions?

Is orforglipron safe?

Orforglipron has a safety profile similar to other GLP-1 medicines in large trials: stomach and bowel side effects are common, and serious problems such as pancreatitis and gallbladder disease are uncommon but real. The label lists who should not take it and what to watch for, and those findings apply to the approved tablets at labeled doses. It is new, so rare side effects that only appear after millions of prescriptions are not yet known, and unapproved products carry risks of their own. [1], [27], [35]

What are the most common side effects?

Stomach and bowel symptoms. In the two main weight trials, people on the 5.5, 9 and 17.2 mg tablet-equivalent doses reported: [1]

[1]

Burping, bloating, reflux and wind were also more common. Trials record these as adverse events, whether or not the drug caused them. Of the people who had stomach or bowel side effects, 60% called them mild, 36% moderate and 4% severe, and they were most frequent while the dose was rising. Overall, 6% to 10% of people stopped because of side effects, compared with 3% on placebo, mostly for stomach reasons. [1] In a year-long open-label safety study in Japanese adults with type 2 diabetes, 5%, 8% and 14% stopped because of side effects on the 3, 12 and 36 mg capsules. [66]

What serious risks are on the label?

• Thyroid tumors (US boxed warning). Other GLP-1 drugs caused thyroid C-cell tumors in rats and mice. The US label carries the same boxed warning and rules out use in anyone with a personal or family history of medullary thyroid cancer or the inherited condition MEN 2 (see thyroid risk). [1]
• Pancreatitis. Inflammation of the pancreas, sometimes severe. In the weight trials it was confirmed in 6 people on orforglipron and 1 on placebo (0.14 versus 0.04 people per 100 years of treatment). Severe stomach pain that may spread to the back needs urgent care, and the tablets are stopped. The UK label says it has not been studied in people who have had pancreatitis. [1], [8]
• Severe stomach and bowel reactions. About 3% had severe reactions, versus 1% on placebo. It is not recommended with severe gastroparesis (a stomach that empties very slowly). [1]
• Kidney injury from dehydration. Reported in 0.2% versus 0.05%, mostly after vomiting or diarrhea. [1]
• Gallbladder disease. Gallstones in 1% versus 0.7%, and gallbladder inflammation in 0.4% versus 0.3%, linked to weight loss. [1]
• Low blood sugar (hypoglycemia). In ATTAIN-2, in adults with type 2 diabetes, 2% on orforglipron had low blood sugar versus 0.2% on placebo, and one person on orforglipron had a severe episode. The risk is higher with a sulfonylurea (7% versus 0.5% of those not taking one) or insulin, and low blood sugar has also been reported in people without diabetes. [1]
• Faster heart rate and low blood pressure. Resting heart rate rose by 4 to 5 beats per minute on average; a fast heart rate was reported in 3% versus 0.9%. Low blood pressure affected 2% versus 0.5%, and 4% of those also on blood-pressure medicines. [1]
• Allergic reactions. In the weight trials, allergic (hypersensitivity) reactions of any severity occurred in 0.5% of people on orforglipron versus 0.3% on placebo; this count includes anaphylaxis (a severe, whole-body allergic reaction), whose separate rate the label does not give. Signs of a serious reaction, such as swelling of the face, lips or throat, or trouble breathing, mean stopping the tablets and getting medical help promptly. Anyone who has had a serious allergic reaction to orforglipron or the tablet's other ingredients should not take it. [1], [8]
• Diabetic eye disease and anesthesia. Rapid improvement in blood sugar can temporarily worsen diabetic eye disease. Because the stomach empties more slowly, food could be inhaled into the lungs under general anesthesia or deep sedation, so tell the care team before any procedure. [1]

Blood tests also change: pancreas enzymes (amylase and lipase) rose on average by 16% to 31%, which does not by itself mean pancreatitis. Skin sensations such as tingling or burning (dysesthesia) affected 1% on the top dose. [1]

Is orforglipron hard on the liver?

The liver question matters because Pfizer stopped developing two other small-molecule GLP-1 pills: lotiglipron in 2023, citing drug-interaction data and raised liver enzymes, and danuglipron in 2025, after one participant had a possible drug-caused liver injury that resolved when the drug was stopped. [67], [68] Orforglipron is broken down by the liver, so regulators looked closely. In a pooled analysis of the phase 3 program covering 11,220 people, a pattern of liver-enzyme and bilirubin rises that can signal serious drug-caused liver injury occurred in 6 people on orforglipron and 6 on comparison treatments (about 0.1% each), and none was judged to be caused by orforglipron. Rare liver injury cannot be ruled out until far more people have taken it. [48]

Does orforglipron cause thyroid cancer?

It is not known, and the reason differs from other GLP-1 drugs. For semaglutide and similar drugs, the warning comes from thyroid tumors seen in rats and mice. Orforglipron does not act on rat or mouse GLP-1 receptors, and it caused no tumors in a 2-year rat study or a 26-week study in mice bred to show cancer risk quickly. That result cannot clear it, because the rodents could not respond to it. The US label keeps the class-wide boxed warning and says the human relevance of these rodent tumors has not been determined. [1]

The UK label handles this differently: its only contraindication is allergy to the ingredients, with no thyroid-cancer contraindication. Human studies of GLP-1 drugs as a group disagree: a French study found a higher risk of thyroid cancer, while a Scandinavian study did not. Neither included orforglipron. Routine calcitonin blood tests or thyroid scans are of uncertain value, according to the US label; a lump in the neck, hoarseness, trouble swallowing or shortness of breath should be reported. [8], [69], [70], [1]

Can orforglipron affect eyesight or mood?

Eyesight. The UK label lists NAION, a rare sudden loss of vision in one eye from reduced blood flow to the optic nerve, among events reported with GLP-1 medicines after approval. It is a class entry; a link with orforglipron itself has not been shown, and the US label does not list it. Sudden vision loss needs emergency eye care. [8], [1]

Mood. The US Foundayo label has no warning about suicidal thoughts. In January 2026 the FDA asked for that warning to be removed from GLP-1 medicines after a review of 91 placebo-controlled trials found no increased risk. Any mood change is still worth raising with a doctor. [1], [71]

Could "research" orforglipron change the risk?

Yes. Capsules, powders and pills sold online as "research" orforglipron are not Foundayo, and their identity, strength and purity have not been independently tested. Some are sold in combinations, such as with SLU-PP-332, or with added vitamin B6. [11], [12], [24]

In September 2026, the FDA updated an import alert that lets officials hold imported bulk GLP-1 ingredients without examining them, and added orforglipron to it; only manufacturers on the FDA's "Green List" are exempt. In community education groups, members most often described buying grey-market 6 mg capsules, while educators drew a clear line between these and the approved tablets. Dose errors are a further risk: if a 6 mg capsule contains what it claims and behaves like the trial capsule, it matches the 5.5 mg tablet, about seven times the 0.8 mg starting dose. [13], [19]

Is orforglipron legal? Is it FDA approved?

Checked September 24, 2026. Rules differ by country and change often. A "research use only" label does not make any product legal or approved.

United States. Foundayo is an FDA-approved prescription medicine for weight reduction and keeping weight off in adults. The key steps:

• 2018. Chugai licensed the compound (OWL833) to Lilly. [5]
• January 20, 2026. The FDA received Lilly's application. [72]
• April 1, 2026. The FDA approved Foundayo, the first new molecular entity approved under its National Priority Voucher pilot program, 50 days after filing. The FDA decided no special risk program (REMS) was needed. [2], [72], [73]
• August 4, 2026. A label update (S-003) was approved; it removed the light-sensitivity storage wording. [1], [21]
• September 21, 2026. The FDA added orforglipron to its import alert on bulk GLP-1 ingredients. [13]

Foundayo is not approved in the US for type 2 diabetes. It is not on the FDA's current or resolved drug-shortage lists, and the FDA has published no compounding decision specific to orforglipron; for semaglutide and tirzepatide, shortages were what allowed pharmacies to make routine copies. [74], [75], [76]

Foundayo can be bought for self-pay through LillyDirect, where a partner pharmacy handles the order. In September 2026 the page showed prices starting at $149 a month for 0.8 and 2.5 mg, $199 for 5.5 mg and $299 for 9, 14.5 and 17.2 mg; the 2.5 and 5.5 mg prices are temporary reductions through December 31, 2026, and the $299 price for 14.5 and 17.2 mg requires a refill within 45 days. Lilly also describes a savings offer as low as $25 a month for some people with commercial insurance, and access for eligible Medicare Part D patients at $50 a month from July 2026 through December 2027. Prices and programs can change. [77], [78]

United Kingdom. On August 10, 2026, the MHRA authorised Foundayo for weight management and for type 2 diabetes in adults, the first approval in Europe. It is prescription-only and was not yet available on the NHS, pending an evaluation by NICE. [7], [8]

European Union. Under review. At its September 14–17, 2026 meeting, the European Medicines Agency's medicines committee listed orforglipron at the "list of outstanding issues" stage, with Lilly asking for more time to respond; it was not among the medicines recommended for approval. [79], [80]

Canada. Under review. Health Canada lists orforglipron calcium as a new active substance whose submission has been under review since January 2026; no approval had been issued. [81]

Australia. Under evaluation by the Therapeutic Goods Administration (TGA) since January 2026, under the proposed name Nexvound, for weight management and type 2 diabetes; not yet on the register of approved medicines. Pharmacies in Australia may not compound GLP-1 medicines. [9], [82]

Japan and elsewhere. Chugai reported in April 2026 that orforglipron was under regulatory review in more than 40 countries, including Japan; no Japanese approval had been announced. Switzerland's regulator received a complete application in January 2026. In India, an expert committee recommended permission to import and market the tablets in May 2026, which is not yet a final approval. In China, Lilly filed for type 2 diabetes and obesity in late 2025, according to a local government report. No approval outside the US and UK was found. [83], [84], [85], [86]

Is orforglipron banned in sport?

It is not banned. Orforglipron is not named on the World Anti-Doping Agency's 2026 or 2027 Prohibited Lists, or on its Monitoring Programs, which track semaglutide and tirzepatide without banning them. The US Anti-Doping Agency's athlete guidance on GLP-1 medicines lists Foundayo and says these medicines are not prohibited in sport. Rules can change each year, so athletes should check the current list. [87], [88], [89], [90], [91]

Who should be especially cautious?

• Pregnancy and breastfeeding. Weight loss offers no benefit in pregnancy. The US label says to stop when pregnancy is recognized; the UK label says not to use it in pregnancy and to stop at least 3 weeks before a planned pregnancy. In a small rabbit study, very high exposures (14 times the human level) caused malformations in 2 fetuses; the main rabbit study and a monkey study found no effects, though the monkeys could not be given high doses. It passed into rat milk, and neither label recommends breastfeeding. A pregnancy registry is planned. [1], [8]
• Birth-control pills. Because orforglipron slows the stomach, both labels advise switching to a non-oral method or adding a barrier method for 30 days after starting and for 30 days after each dose increase. Patches, rings, implants and injections are not affected. [1], [8]
• Thyroid cancer history. Medullary thyroid cancer or MEN 2 in you or your family rules it out in the US. [1]
• Past allergic reaction to it. In the US, a previous serious allergic reaction to orforglipron or any ingredient in the tablets rules it out; the UK label rules it out after any allergy to them. Take extra care with a history of anaphylaxis or facial swelling from another GLP-1 medicine. [1], [8]
• Past pancreatitis, gallbladder disease or bowel disease. These need extra care; it is not recommended with severe gastroparesis. In community education groups, one member decided against it because of diverticulitis and a removed gallbladder, a good example of a question to raise with a prescriber. [1], [8]
• Liver disease. Not recommended with severe liver impairment. [1]
• Very severe heart failure. The UK label does not recommend it for people with the most severe stage of heart failure (NYHA class IV, symptoms even at rest), because no one in that group has been studied. [8]
• Under 18. Not approved for children or teenagers; trials in these ages are under way. [1], [34]
• Older adults. In the main trials, 13% of people on orforglipron were 65 or older, and no overall differences in safety or effect were seen. [1], [51]
• Upcoming surgery or sedation. Tell the care team, because of the risk of food in the stomach under anesthesia. [1]
• Drug-tested athletes. Not prohibited (see sport). [89]
• People taking other medicines; see the next question.

Can orforglipron be taken with other medicines?

Several interactions are known, because orforglipron is cleared by the liver enzyme CYP3A4 and slows the stomach. [1], [8]

• Strong CYP3A4 blockers (for example clarithromycin, which raised orforglipron levels 3.5-fold): top dose 9 mg. Avoid blockers that also block the OATP1B transporter (which carries drugs into liver cells), such as ritonavir. In the UK, OATP1B blockers such as ciclosporin (2.6-fold) also cap the dose at 9 mg. [1], [8], [92]
• Strong CYP3A4 boosters (for example carbamazepine, which cut levels by 82%): avoid. With moderate boosters, the prescriber watches whether it still works. [1]
• Statins: keep simvastatin at 20 mg a day or less (its active form rose 2- to 2.5-fold); the UK label advises halving the simvastatin dose and caution with rosuvastatin above 20 mg. [1], [8]
• Oral topotecan (a cancer medicine taken by mouth): the UK label asks for careful monitoring for side effects when it is taken with orforglipron, so the combination is one for the cancer care team to review. [8]
• Insulin and sulfonylureas: higher risk of low blood sugar; the prescriber may lower their dose at the start. [1]
• Birth-control pills and other pills: see above. Acid-reducing medicines such as esomeprazole do not interact. [1]
• Other GLP-1 medicines: the US label says using it with another GLP-1 receptor agonist is not recommended. [1]

In community education groups, a few members discussed adding orforglipron to retatrutide, an experimental injectable drug, for appetite; there are no data on this, and it goes against the label. Bring a full list of everything you take, including supplements, to a pharmacist or doctor. [1]

What is still unknown?

• Long-term outcomes. No completed trial has shown fewer heart attacks, strokes or deaths; ACHIEVE-4's non-inferiority result is not yet in a journal. [55]
• What happens after stopping orforglipron itself. [1]
• Rare harms, including liver injury, that only large-scale use can reveal. [48]
• Children, pregnancy and people with past pancreatitis, who were not studied or were excluded. [1], [8]
• Research products, whose contents are unknown. [13]

What should be monitored while using orforglipron?

Because orforglipron is an approved medicine, its labels tell prescribers what to watch. They do not set one blood-test schedule for everyone; most checks depend on your other conditions, your other medicines and any symptoms. Use this summary to prepare questions for your prescriber; it is not a personal testing plan. [1], [8]

What do the labels ask prescribers to check?

[1], [8]

What else is worth discussing during care?

These effects were seen in the trials or are described in the labels, but the labels do not set a specific check for them. They are reasonable things to track and raise with a prescriber.

[1], [8]

What did the trials measure?

Beyond weight, the main trials tracked waist size, blood pressure, pulse, HbA1c, blood fats (total, LDL, HDL and non-HDL cholesterol and triglycerides), liver enzymes, pancreas enzymes and calcitonin, a thyroid marker; a subgroup had body-composition scans. These research measurements are not all standing clinical requirements. [1], [19], [48]

How is the response judged?

The label ties each step up to "treatment response and tolerability" but sets no target. US diabetes standards (American Diabetes Association, 2026) advise checking an obesity medicine's benefits and safety at least monthly for 3 months, then at least every 3 months, and reassessing the plan if weight loss is under about 5% after 3 months. [1], [93]

Weight is only one outcome. People often care more about blood sugar, blood pressure, eating patterns or how far they can walk, and trials measure these separately. Tracking what matters to you, alongside dose changes and side effects, makes a conversation with your prescriber more useful.

What do people in public communities report?

Foundayo has been on sale only since April 2026, so public accounts are new and short, mostly one to four months. They include steady losses, stalls, side effects, disappointing switches from injections and research-product experiments. Discussions in community education groups are summarized here without identifying anyone.

What do the positive reports look like?

The clearest positive accounts give weights and tablet strengths. One person reported going from 205 to 191 lb in 60 days (30 days each at 0.8 and 2.5 mg), with less hunger and "food noise", while also exercising more as hip pain eased. Another reported 242 to 213 lb in a little over 3 months on 0.8 then 2.5 mg, following a clinic's diet advice. A third reported 194 to 164 lb and had just moved up to 5.5 mg. [94], [95], [96]

Some people did well without moving up. One stayed at 0.8 mg and reported 155 to 142 lb by the end of month 3, alongside strength training; another reported a postpartum drop from 154 to 133 lb over 4 months on up to 5.5 mg. [97], [98]

How long do results take?

Accounts describe appetite changing within the first days or weeks and weight falling gradually over months. One person described more hunger toward the end of a 30-day step, before the next increase. One trial participant described early loss, then about 6 months without further change and some return of food noise, without knowing whether they were on the drug or placebo. [96], [99], [100]

What happens when people switch from injections?

This is the most common disappointment. People moving from tirzepatide or semaglutide described more hunger, cravings returning and small gains, especially at 0.8 or 2.5 mg: one gained 4 lb in a month and went back to tirzepatide; another gained 10 lb in the first two months, then held steady. One person on 17.2 mg after Zepbound reported headaches, nausea and an 8 lb gain over about 3.5 weeks, and planned to switch back. Others kept their weight, and one said appetite control felt steadier on 9 mg. One person who went the other way, from Foundayo to Mounjaro, said they felt better within days. [40], [39], [101], [102], [103]

In community education groups, members generally saw orforglipron as weaker than the injectable drugs but as their preferred pill option, a view that no head-to-head obesity trial has tested. The few disappointed accounts reviewed there all followed a switch from a stronger injectable drug, apparently at low starting strengths. The ATTAIN-MAINTAIN trial started switchers at a higher dose (see switching). [25]

Does everyone lose weight?

No. One person who moved from Wegovy injections described no reduction in appetite or food noise on Foundayo and regained about 5 lb during the early steps. Another saw neither loss nor gain over 12 days on 0.8 mg after Zepbound. A clinical-trial participant described no appetite or weight change, but may have been on placebo. [38], [37], [104]

What about unwanted effects?

Nausea, reflux, bloating, constipation and tiredness come up most, usually early or after a step up. One first-time user started at 2.5 mg, skipping the 0.8 mg step, and described stomach pain, nausea and fullness on day 2. Another stopped after nausea, heartburn, flu-like symptoms and lightheadedness during exertion, one episode of which happened in the heat. [94], [105], [97], [106], [107]

These are individual reports. A forum post cannot show whether orforglipron caused a symptom or how often it happens; the risks section gives the trial rates.

What about research products?

A small number of public posts describe claimed research pills or capsules, often from one enthusiastic poster who linked to a seller, reporting appetite suppression within hours or days. One person cut claimed 6 mg grey-market tablets into halves and quarters, first reported fewer cravings, then edited the comment to say the lower amounts had not worked or had stopped working. None of these products was tested. [108], [109], [99]

How can you judge a weight-loss story?

Ask: Was it Foundayo or a research product? Which tablet strength, and for how long at each step? Was the person switching from an injection? What else changed, such as diet, exercise, pregnancy or other medicines? What happened a few months later?

These selected discussions show what people experience and the questions research should answer. They are not a survey of all users, a success rate or a substitute for the trials.

How does orforglipron compare with semaglutide, tirzepatide and retatrutide?

These are the medicines most often weighed against orforglipron. All of them act on GLP-1 signaling, but they differ in what they are made of, how they are taken and how far they have got through testing. Status was checked on September 24, 2026.

The weight results come from separate trials in different people, so the table cannot rank these medicines. The one direct comparison, ACHIEVE-3, used diabetes doses: orforglipron lowered HbA1c and weight more than semaglutide tablets, with more stomach side effects. A 2026 statistical comparison across separate obesity trials estimated that the 25 mg semaglutide tablet produced about 3.2 percentage points more weight loss than the 36 mg orforglipron capsule (17.2 mg tablet); such indirect comparisons cannot remove all differences between trials. Semaglutide's heart and kidney benefits come from its own outcome trials, and those results do not carry over to orforglipron. [28], [118]

Common questions about orforglipron

How long does orforglipron take to work?

Weight loss builds over months. It takes at least 60 days to reach 5.5 mg and at least 5 months to reach 17.2 mg, and the main trials measured their results at 72 weeks. [1] Some people describe appetite changing within the first days or weeks, but the trials did not measure when people first notice a change. [94], [96] See what people report.

Is orforglipron the same as oral semaglutide or the Wegovy pill?

No. Semaglutide tablets (Rybelsus, Ozempic tablets and Wegovy tablets) contain a peptide that needs an absorption helper and must be taken on an empty stomach. Orforglipron is a different, non-peptide molecule that can be taken with or without food. In ACHIEVE-3, it lowered HbA1c more than semaglutide tablets at diabetes doses but caused more stomach side effects. [4], [1], [28] See the comparison.

Why do some sites say 36 mg when the top Foundayo dose is 17.2 mg?

Because 36 mg is a trial capsule dose. The trials used capsules on a different milligram scale, and a 36 mg capsule gives the same blood levels as a 17.2 mg tablet. There is no 36 mg tablet, and the labels say never to take more than one tablet a day. [19], [8] See the conversion table.

Can you switch from Zepbound or Wegovy to Foundayo?

Yes, with a prescriber, but there is no milligram conversion between a weekly injection and a daily tablet. The label starts everyone at 0.8 mg. In the ATTAIN-MAINTAIN trial, people switched within 14 days of their last injection to a 12 mg capsule (9 mg tablet), and those whose weight had leveled off kept an estimated 75% to 79% of their weight loss on average, while forum reports from people starting at 0.8 mg often describe hunger returning at first. [1], [25], [37] See switching.

Do you have to take Foundayo on an empty stomach?

No. It can be taken once a day at any time, with or without food or water; a meal lowered blood levels only slightly. Swallow the tablet whole. [1], [8] See why it can be a pill.

What if I miss a dose of Foundayo?

Take it as soon as you remember, but never two tablets in one day. Under the US label, after 7 or more missed days in a row, the dose steps restart at a lower dose, so contact your prescriber. [1], [8] See missed doses.

How much does Foundayo cost?

In the US, LillyDirect listed self-pay prices of $149 to $299 a month depending on the strength, with conditions, and as little as $25 a month for some commercially insured people; insurance coverage varies. Prices change, so check current offers. [77] In the UK, it is not yet available on the NHS. [7]

Are "research" orforglipron capsules the same as Foundayo?

No. They are not approved, their contents have not been independently checked, and their strengths (often 6 mg capsules) do not match Foundayo tablets. The FDA now lets officials hold imported bulk orforglipron from unlisted makers. [11], [13] See research products.

Glossary

Plain explanations of the medical, dosing and research terms used in this guide. Underlined terms in the text link here.

Adverse event

A harmful or unwanted medical event reported after someone used a treatment. A report alone does not prove the treatment caused it.

Animal study

Research in animals such as mice, rats, rabbits or monkeys. It shows what a substance does in a living body, but results in people can differ. Orforglipron does not act on normal rat and mouse GLP-1 receptors, so many of its animal studies used engineered animals or monkeys.

Bioavailability

How much of a dose reaches the bloodstream in a usable form. For orforglipron tablets it is about 77%; for semaglutide tablets it is about 1% to 2%.

Bioequivalence

When two forms of a medicine give matching levels in the blood. Orforglipron trial capsules and Foundayo tablets were matched this way, which is why a 36 mg capsule is matched to a 17.2 mg tablet. The milligrams are not interchangeable, so people follow the product and dose they are prescribed.

BMI (body mass index)

Weight in kilograms divided by height in meters squared. A BMI of 30 or more is classed as obesity in adults, and 27 to under 30 as overweight in the Foundayo labels.

Boxed warning

The most serious type of warning on a US drug label, printed in a box at the top. Foundayo's is about thyroid tumors seen in rodents with other GLP-1 drugs.

C-cells (thyroid)

Cells in the thyroid gland that make the hormone calcitonin. Medullary thyroid cancer starts in these cells.

Cell study (in vitro)

Research on cells or tissue grown in a dish. It gives early clues about biology, but it is far from proof of benefit in people.

Compounding

When a pharmacy prepares a customized medicine from individual ingredients. Compounded drugs are not FDA approved.

Randomized controlled trial

A study that assigns people by chance to a treatment or a comparison, often a placebo, so the groups can be compared fairly.

Course and cycle

A course is a period of repeated use. A cycle is a course plus a planned break. The Foundayo labels describe continuous use, not cycles.

CYP3A4

A liver and gut enzyme that breaks down many medicines, including orforglipron. Drugs that block it raise orforglipron levels; drugs that speed it up lower them.

Dose (amount each time)

The amount taken on one occasion. For Foundayo, one tablet is the whole daily dose.

DXA scan

Dual-energy X-ray absorptiometry: a low-dose X-ray scan that measures fat, lean tissue and bone. It was used in a substudy of ATTAIN-1.

Dysesthesia

Unusual or unpleasant skin sensations such as tingling, burning or pain from light touch.

Efficacy estimand

A way of analyzing a trial that estimates the effect if everyone had kept taking their assigned treatment. It usually shows a bigger effect than the treatment-regimen result.

Gastroparesis

A condition in which the stomach empties very slowly without a blockage. Foundayo is not recommended when it is severe.

GIP (glucose-dependent insulinotropic polypeptide)

Another gut hormone released after eating that boosts insulin. Tirzepatide and retatrutide switch on its receptor; orforglipron does not.

GLP-1 (glucagon-like peptide-1)

A hormone released by the gut after eating. It raises insulin when blood sugar is high, lowers glucagon, slows the stomach and signals fullness to the brain.

GLP-1 receptor agonist

A medicine that switches on the GLP-1 receptor, copying the hormone's effects. Semaglutide and liraglutide are peptide examples; orforglipron is a non-peptide one.

Half-life

The time it takes for the level of a substance in the blood to fall by half. For orforglipron it is about 29 to 49 hours.

Hazard ratio

A comparison of how often an event happens over time in two groups. A value of 1 means no difference, and a value below 1 is an estimate of fewer events in the first group. If the range around it includes 1, the study has not shown a real difference either way.

HbA1c

A blood test that reflects average blood sugar over roughly the past three months. It is the main measure of diabetes control.

Hypoglycemia

Blood sugar that is too low. It can cause shakiness, sweating and confusion, and is more likely when a GLP-1 medicine is combined with insulin or sulfonylureas.

Investigational

Still being tested and not approved for the use or form in question. Orforglipron capsules used in trials are investigational; Foundayo tablets are approved in the US and UK.

Lean mass

Everything in the body that is not fat or bone, including muscle, organs and water. A body scan measures it; it is not the same as muscle strength.

Maintenance dose

The dose a person stays on after the step-up period ends. For Foundayo it can be 5.5, 9, 14.5 or 17.2 mg a day.

Milligram (mg)

A thousandth of a gram. Orforglipron doses are written in mg; 1 mg equals 1,000 micrograms (mcg).

NAION

Non-arteritic anterior ischemic optic neuropathy: sudden, usually painless vision loss in one eye caused by reduced blood flow to the optic nerve.

Non-inferiority trial

A trial designed to show that a treatment is not worse than a comparison by more than a set margin. Passing it does not show the treatment is better.

OATP1B

A pair of transporter proteins in the liver that carry many medicines, including orforglipron, from the blood into liver cells. Drugs that block them, such as ritonavir or ciclosporin, can raise orforglipron levels.

Oral

Taken by mouth and swallowed, as a tablet.

Pancreatitis

Inflammation of the pancreas. It causes severe upper stomach pain, often spreading to the back, and needs urgent care.

Partial agonist

A drug that switches a receptor on, but less fully than the natural signal. Orforglipron is a partial agonist of the GLP-1 receptor in laboratory tests.

Peptide

A short chain of amino acids. GLP-1 and semaglutide are peptides; orforglipron is not.

Pharmacokinetics

How the body absorbs, moves, breaks down and removes a substance.

Placebo

A dummy treatment with no active ingredient, used as a comparison in studies.

Preclinical research

Cell and animal studies of how a substance works and what harm it might cause, including the safety tests regulators require.

Small molecule

A drug made of a relatively small chemical structure, usually built by chemical synthesis. Small molecules are often absorbed well from the gut, unlike most peptides.

Steady state

The point at which levels in the blood stop building up because the amount taken matches the amount removed. With daily orforglipron it takes about a week.

Subcutaneous (SC)

Injected into the fatty layer just under the skin. Semaglutide, tirzepatide and retatrutide injections use this route; orforglipron is not injected.

Tapering

Lowering a dose in steps before stopping. No study has tested whether tapering off orforglipron limits weight regain.

Titration

Adjusting a dose in steps, usually starting low and increasing. Foundayo steps up at least 30 days apart.

Treatment regimen estimand

A way of analyzing a trial that counts everyone assigned to a treatment, including people who stopped taking it. It is the main result in the orforglipron labels and journals.

Type 2 diabetes

A long-term condition in which the body does not use insulin well, so blood sugar runs too high.

WADA

The World Anti-Doping Agency, which publishes the list of substances banned in sport and a separate Monitoring Program of substances it tracks without banning.

How this guide was researched

This guide is built from a thorough review of the sources cited throughout it: product labels from the US and UK, the FDA's review of the application, published clinical trials and studies, clinical-trial registry records, regulatory documents and published dosing descriptions. We also reviewed public online forums and community education groups where people describe their own experiences with orforglipron.

The guide cites 118 sources, including 28 original research papers on people, cells or animals (22 human studies and 6 cell and animal studies). Only a handful of animal studies exist, because orforglipron does not act on normal rat and mouse receptors. Each type of source answers a different question. Labels and trials show what was approved and measured. Dosing descriptions show how orforglipron is typically discussed and used. Personal accounts show what individual people experienced. Every numbered citation links to its entry below, labeled by source type.

How this guide was made

Research and drafting were AI-assisted. Every cited source was checked against the original, and the guide was reviewed and edited by Doserly before publication. It has not had an independent clinical review, and Doserly does not currently have medical reviewers. Doserly makes a medication and health-tracking app and runs Doserly Academy, both of which are promoted in this guide. Read our editorial policy for how guides are researched, updated and corrected.

This guide is for educational purposes. It summarizes what the reviewed sources report so the research is easier to understand; it is not medical advice. For a deeper dive, or to check any point for yourself, go straight to the cited sources.

Explore the sources